Drug-like Antagonists of P2Y Receptor Subtypes: An Update.

ABSTRACT: The hunt for drug-like P2YR antagonists continues, stimulated by ever-increasing pharmacological evidence for their clinical benefit and the astonishing array of biological functions which they orchestrate, including platelet aggregation, cancer proliferation, pain, neurodegenerative diseases, and immune regulation. Extensive research has identified modulators of P2Y receptors. However, only a limited number of small-molecule antagonists for the P2Y₁₂ receptor have received approval for their clinical use. Recent pioneering discoveries of small-molecule ligand-bound X-ray crystal structures for the P2Y₁ and P2Y₁₂ receptors and homology modeling has stimulated research groups to explore orthosteric and allosteric receptor antagonists, aided in part by the di

SUBMITTER: Puthanveedu M 

PROVIDER: S-EPMC12067450 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature